Compare GSK plc (GSK) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs T Rowe Price Group Inc — how do they compare? GSK plc trades at $52.38 (market cap $101.34B), while T Rowe Price Group Inc trades at $119.56 (market cap $25.41B). The key difference: GSK plc is far larger — about 4× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.39%). Which is the better fit depends on your goals.
| GSK | TROW | |
|---|---|---|
Market Cap | $101.34B | $25.41B |
Sector | Health | Financials |
52-Week High | $61.18 | $120.16 |
52-Week Low | $36.20 | $86.19 |
Enterprise Value | $121.95B | $22.12B |
Dividend Yield | 3.49% | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
T. Rowe Price (TROW) trades at $116.07, up 2.13% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 12.72, net income margin of 28.28%, and consistent earnings beats. Recent AUM growth to $1.89 trillion and strategic institutional enhancements support positive momentum. Technical indicators show the stock trading near pivot point resistance at $116 with support at $115.
TROW presents a compelling value opportunity with attractive valuation metrics and strong profitability. The primary risk remains equity outflows despite diversification efforts. Analyst consensus is cautious with 63% hold ratings, though recent Zacks upgrades to Strong Buy highlight growing optimism. The stock's current price sits above the consensus target of $109.17, suggesting limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
